HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology
Market Cap$1.82B
5Y Perf.-11.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HRMY vs AVPT
Revenue, margins, valuation, and 5-year total return — side by side.
AVPT
AvePoint, Inc.
Software - Infrastructure
Market Cap$2.23B
5Y Perf.+1.3%
HRMY vs AVPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HRMY | AVPT |
|---|---|---|
| Industry | Biotechnology | Software - Infrastructure |
| Market Cap | $1.82B | $2.23B |
| Revenue (TTM) | $899M | $444M |
| Net Income (TTM) | $146M | $47M |
| Gross Margin | 76.5% | 73.7% |
| Operating Margin | 21.1% | 9.6% |
| Forward P/E | 9.0x | 27.7x |
| Total Debt | $240M | $10M |
| Cash & Equiv. | $753M | $481M |
HRMY vs AVPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HRMY
AVPT
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 100 | 88.7 | -11.3% |
| AvePoint, Inc. (AVPT) | 100 | 101.3 | +1.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HRMY vs AVPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HRMY leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AvePoint, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
HRMY
Harmony Biosciences Holdings, Inc.
The Income Pick
HRMY carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.79
- Lower volatility, beta 0.79, Low D/E 27.5%, current ratio 3.60x
- Beta 0.79, current ratio 3.60x
Best for: income & stability and sleep-well-at-night
AVPT
AvePoint, Inc.
The Growth Play
AVPT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 26.9%, EPS growth 193.8%, 3Y rev CAGR 21.8%
- 5.5% 10Y total return vs HRMY's -15.1%
- 26.9% revenue growth vs HRMY's 21.5%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVPT | 26.9% revenue growth vs HRMY's 21.5% |
| Value | HRMY | Lower P/E (9.0x vs 27.7x) |
| Quality / Margins | HRMY | 16.2% margin vs AVPT's 10.5% |
| Stability / Safety | HRMY | Beta 0.79 vs AVPT's 1.06 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | HRMY | -6.0% vs AVPT's -40.0% |
| Efficiency (ROA) | HRMY | 12.0% ROA vs AVPT's 6.3%, ROIC 42.0% vs 11.4% |
HRMY vs AVPT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
HRMY vs AVPT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHRMYLAGGINGAVPT
AVPTAvePoint, Inc.
0leads
HRMYHarmony Biosciences H…
3leads
6 Total Categories
CATEGORYLEADERvs AVPTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HRMY4/6
Valuation MetricsMultiples, price ratios, and targets
HRMY6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
HRMY2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HRMY leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HRMY is the larger business by revenue, generating $899M annually — 2.0x AVPT's $444M. HRMY is the more profitable business, keeping 16.2% of every revenue dollar as net income compared to AVPT's 10.5%. On growth, AVPT holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $899M | $444M |
| EBITDAEarnings before interest/tax | $209M | $47M |
| Net IncomeAfter-tax profit | $146M | $47M |
| Free Cash FlowCash after capex | $342M | $105M |
| Gross MarginGross profit ÷ Revenue | +76.5% | +73.7% |
| Operating MarginEBIT ÷ Revenue | +21.1% | +9.6% |
| Net MarginNet income ÷ Revenue | +16.2% | +10.5% |
| FCF MarginFCF ÷ Revenue | +38.0% | +23.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +16.6% | +26.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -29.5% | +3.6% |
HRMY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
HRMY leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 11.6x trailing earnings, HRMY trades at a 83% valuation discount to AVPT's 68.8x P/E. On an enterprise value basis, HRMY's 5.6x EV/EBITDA is more attractive than AVPT's 44.8x.
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| Market CapShares × price | $1.8B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | 11.59x | 68.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.95x | 27.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 5.58x | 44.79x |
| Price / SalesMarket cap ÷ Revenue | 2.09x | 5.31x |
| Price / BookPrice ÷ Book value/share | 2.11x | 4.94x |
| Price / FCFMarket cap ÷ FCF | 5.23x | 27.32x |
HRMY leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — HRMY and AVPT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
HRMY delivers a 17.2% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $10 for AVPT. AVPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HRMY's 0.28x. On the Piotroski fundamental quality scale (0–9), AVPT scores 6/9 vs HRMY's 4/9, reflecting solid financial health.
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +17.2% | +10.2% |
| ROA (TTM)Return on assets | +12.0% | +6.3% |
| ROICReturn on invested capital | +42.0% | +11.4% |
| ROCEReturn on capital employed | +22.6% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.28x | 0.02x |
| Net DebtTotal debt minus cash | -$513M | -$471M |
| Cash & Equiv.Liquid assets | $753M | $481M |
| Total DebtShort + long-term debt | $240M | $10M |
| Interest CoverageEBIT ÷ Interest expense | 21.78x | — |
Evenly matched — HRMY and AVPT each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — HRMY and AVPT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HRMY five years ago would be worth $11,335 today (with dividends reinvested), compared to $10,168 for AVPT. Over the past 12 months, HRMY leads with a -6.0% total return vs AVPT's -40.0%. The 3-year compound annual growth rate (CAGR) favors AVPT at 32.6% vs HRMY's -4.5% — a key indicator of consistent wealth creation.
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -15.9% | -21.9% |
| 1-Year ReturnPast 12 months | -6.0% | -40.0% |
| 3-Year ReturnCumulative with dividends | -12.8% | +133.0% |
| 5-Year ReturnCumulative with dividends | +13.3% | +1.7% |
| 10-Year ReturnCumulative with dividends | -15.1% | +5.5% |
| CAGR (3Y)Annualised 3-year return | -4.5% | +32.6% |
Evenly matched — HRMY and AVPT each lead in 3 of 6 comparable metrics.
Risk & Volatility
HRMY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HRMY is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than AVPT's 1.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HRMY currently trades 76.9% from its 52-week high vs AVPT's 51.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.06x |
| 52-Week HighHighest price in past year | $40.87 | $20.25 |
| 52-Week LowLowest price in past year | $25.52 | $8.83 |
| % of 52W HighCurrent price vs 52-week peak | +76.9% | +51.0% |
| RSI (14)Momentum oscillator 0–100 | 67.6 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 791K | 1.6M |
HRMY leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HRMY as "Buy" and AVPT as "Buy". Consensus price targets imply 69.6% upside for AVPT (target: $18) vs 48.9% for HRMY (target: $47).
| Metric | HRMYHarmony Bioscienc… | AVPTAvePoint, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $46.80 | $17.50 |
| # AnalystsCovering analysts | 13 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
HRMY leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallHarmony Biosciences Holding… (HRMY)Leads 3 of 6 categories
Loading custom metrics...
HRMY vs AVPT: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HRMY or AVPT a better buy right now?
For growth investors, AvePoint, Inc.
(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 21. 5% for Harmony Biosciences Holdings, Inc. (HRMY). Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 11. 6x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HRMY or AVPT?
On trailing P/E, Harmony Biosciences Holdings, Inc.
(HRMY) is the cheapest at 11. 6x versus AvePoint, Inc. at 68. 8x. On forward P/E, Harmony Biosciences Holdings, Inc. is actually cheaper at 9. 0x.
03Which is the better long-term investment — HRMY or AVPT?
Over the past 5 years, Harmony Biosciences Holdings, Inc.
(HRMY) delivered a total return of +13. 3%, compared to +1. 7% for AvePoint, Inc. (AVPT). Over 10 years, the gap is even starker: AVPT returned +5. 5% versus HRMY's -15. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HRMY or AVPT?
By beta (market sensitivity over 5 years), Harmony Biosciences Holdings, Inc.
(HRMY) is the lower-risk stock at 0. 79β versus AvePoint, Inc. 's 1. 06β — meaning AVPT is approximately 34% more volatile than HRMY relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 28% for Harmony Biosciences Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HRMY or AVPT?
By revenue growth (latest reported year), AvePoint, Inc.
(AVPT) is pulling ahead at 26. 9% versus 21. 5% for Harmony Biosciences Holdings, Inc. (HRMY). On earnings-per-share growth, the picture is similar: AvePoint, Inc. grew EPS 193. 8% year-over-year, compared to 8. 0% for Harmony Biosciences Holdings, Inc.. Over a 3-year CAGR, HRMY leads at 25. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HRMY or AVPT?
Harmony Biosciences Holdings, Inc.
(HRMY) is the more profitable company, earning 18. 3% net margin versus 8. 4% for AvePoint, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRMY leads at 24. 0% versus 7. 9% for AVPT. At the gross margin level — before operating expenses — HRMY leads at 77. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HRMY or AVPT more undervalued right now?
On forward earnings alone, Harmony Biosciences Holdings, Inc.
(HRMY) trades at 9. 0x forward P/E versus 27. 7x for AvePoint, Inc. — 18. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 69. 6% to $17. 50.
08Which pays a better dividend — HRMY or AVPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is HRMY or AVPT better for a retirement portfolio?
For long-horizon retirement investors, Harmony Biosciences Holdings, Inc.
(HRMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79)). Both have compounded well over 10 years (HRMY: -15. 1%, AVPT: +5. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HRMY and AVPT?
These companies operate in different sectors (HRMY (Healthcare) and AVPT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HRMY: 16.6% · AVPT: 26.0%)Net Margin>
%
(HRMY: 16.2% · AVPT: 10.5%)P/E Ratio<
x
(HRMY: 11.6x · AVPT: 68.8x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.